Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brain metastases.
Ewend MG, Carey LA, Morris DE, Harvey RD, Hensing TA. Ewend MG, et al. Among authors: harvey rd. Curr Treat Options Oncol. 2001 Dec;2(6):537-47. doi: 10.1007/s11864-001-0075-8. Curr Treat Options Oncol. 2001. PMID: 12057099 Review.
Serotonin antagonists. An update.
Harvey RD 3rd, Lindley CL. Harvey RD 3rd, et al. Cancer Pract. 1998 Mar-Apr;6(2):133-5. doi: 10.1046/j.1523-5394.1998.1998006133.x. Cancer Pract. 1998. PMID: 9573914 Review. No abstract available.
Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research Statement.
Thota R, Hurley PA, Miller TM, Bruinooge SS, Lipset C, Harvey RD, Black LJ, Dinsdale A, Merrill JK, Pollastro T, Prindiville SA, Rizvi MA, Sherwood S, Nowakowski GS. Thota R, et al. Among authors: harvey rd. J Clin Oncol. 2024 Nov 20;42(33):3986-3995. doi: 10.1200/JCO.24.00961. Epub 2024 Jul 30. J Clin Oncol. 2024. PMID: 39079075
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Juric D, Barve M, Vaishampayan U, Roda D, Calvo A, Jañez NM, Trigo J, Greystoke A, Harvey RD, Olszanski AJ, Opyrchal M, Spira A, Thistlethwaite F, Jiménez B, Sappal JH, Kannan K, Riley J, Li C, Li C, Gregory RC, Miao H, Wang S. Juric D, et al. Among authors: harvey rd. Cancer Med. 2024 Mar;13(5):10.1002/cam4.6776. doi: 10.1002/cam4.6776. Cancer Med. 2024. PMID: 38501219 Free PMC article. Clinical Trial.
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
Falchook G, Patnaik A, Richardson DL, Harvey RD, Sharma MR, Hafez N, Hamilton E, Piha-Paul SA, Barve M, Wise-Draper T, Patel MR, Dowlati A, Pascuzzo J, Tang SC, Faltermeier C, Malinowska IA, Shtessel L, Striha A, Potocka E. Falchook G, et al. Among authors: harvey rd. Clin Ther. 2024 Mar;46(3):228-238. doi: 10.1016/j.clinthera.2024.01.004. Epub 2024 Feb 28. Clin Ther. 2024. PMID: 38423866 Free article. Clinical Trial.
A call to action to advance patient-focused and decentralized clinical trials.
Harvey RD, Miller TM, Hurley PA, Thota R, Black LJ, Bruinooge SS, Boehmer LM, Fleury ME, Kamboj J, Rizvi MA, Symington BE, Tap WD, Waterhouse DM, Levit LA, Merrill JK, Prindiville SA, Pollastro T, Brewer JR, Byatt LP, Hamroun L, Kim ES, Holland N, Nowakowski GS. Harvey RD, et al. Cancer. 2024 Apr 15;130(8):1193-1203. doi: 10.1002/cncr.35145. Epub 2024 Jan 9. Cancer. 2024. PMID: 38193828 No abstract available.
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.
Carneiro BA, Cavalcante L, Mahalingam D, Saeed A, Safran H, Ma WW, Coveler AL, Powell S, Bastos B, Davis E, Sahai V, Mikrut W, Longstreth J, Smith S, Weisskittel T, Li H, Borden BA, Harvey RD, Sahebjam S, Cervantes A, Koukol A, Mazar AP, Steeghs N, Kurzrock R, Giles FJ, Munster P. Carneiro BA, et al. Among authors: harvey rd. Clin Cancer Res. 2024 Feb 1;30(3):522-531. doi: 10.1158/1078-0432.CCR-23-1916. Clin Cancer Res. 2024. PMID: 37982822 Clinical Trial.
264 results